CANNAPHARMARX, INC.: 10-Q filed 2023-11-17

Name: CANNAPHARMARX, INC.: 10-Q filed 2023-11-17
Creator: CANNAPHARMARX, INC.

What CANNAPHARMARX, INC. reported in its quarterly report filed 2023-11-17 (fiscal Q3 2023): 34 published measures, 106 facts as tagged in accession 0001683168-23-008281.

This filing

Form: 10-Q (quarterly report)
Filed: 2023-11-17
Fiscal period: fiscal Q3 2023
Accession: 0001683168-23-008281 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CANNAPHARMARX, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2023-09-30	5,155,989	USD
At 2022-12-31	5,414,176	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2023-09-30	25,785,964	USD
At 2022-12-31	22,758,632	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2023-09-30	-20,629,975	USD
At 2023-06-30	-20,143,984	USD
At 2023-03-31	-18,210,425	USD
At 2022-12-31	-17,344,456	USD
At 2022-09-30	-14,984,729	USD
At 2022-06-30	-14,704,161	USD
At 2022-03-31	-14,287,091	USD
At 2021-12-31	-12,925,920	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2023-09-30	0	USD
At 2022-12-31	2,317	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-564,368	USD	92
2023-01-01 to 2023-09-30	-3,856,525	USD	273
2023-04-01 to 2023-06-30	-1,879,584	USD	91
2023-01-01 to 2023-03-31	-1,412,573	USD	90
2022-07-01 to 2022-09-30	-1,313,248	USD	92
2022-01-01 to 2022-09-30	-4,891,559	USD	273
2022-04-01 to 2022-06-30	-1,506,329	USD	91
2022-01-01 to 2022-03-31	-2,071,982	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	-970,032	USD	273
2022-01-01 to 2022-09-30	-356,894	USD	273

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	78,880	USD	273
2022-01-01 to 2022-09-30	106,886	USD	273

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

Period	Unit	Days
2023-07-01 to 2023-09-30	USD	92
2023-01-01 to 2023-09-30	USD	273
2022-07-01 to 2022-09-30	USD	92
2022-01-01 to 2022-09-30	USD	273

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	1,046,595	USD	273
2022-01-01 to 2022-09-30	443,515	USD	273

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	-78,880	USD	273
2022-01-01 to 2022-09-30	-106,886	USD	273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2023-09-30	-98,551,864	USD
At 2022-12-31	-94,695,339	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	295,096,003	shares	92
2023-01-01 to 2023-09-30	292,670,792	shares	273
2022-07-01 to 2022-09-30	241,098,037	shares	92
2022-01-01 to 2022-09-30	197,052,865	shares	273

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	295,096,003	shares	92
2023-01-01 to 2023-09-30	292,670,792	shares	273
2022-07-01 to 2022-09-30	241,098,037	shares	92
2022-01-01 to 2022-09-30	197,052,865	shares	273

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	0	USD/shares	92
2023-01-01 to 2023-09-30	-0.01	USD/shares	273
2022-07-01 to 2022-09-30	0	USD/shares	92
2022-01-01 to 2022-09-30	-0.02	USD/shares	273

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	0	USD/shares	92
2023-01-01 to 2023-09-30	-0.01	USD/shares	273
2022-07-01 to 2022-09-30	0	USD/shares	92
2022-01-01 to 2022-09-30	-0.02	USD/shares	273

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2023-09-30	167,483	USD
At 2022-12-31	107,780	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	45,245	USD	92
2023-01-01 to 2023-09-30	135,734	USD	273
2022-07-01 to 2022-09-30	45,245	USD	92
2022-01-01 to 2022-09-30	135,734	USD	273

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-667,497	USD	92
2023-01-01 to 2023-09-30	-2,280,713	USD	273
2022-07-01 to 2022-09-30	-588,475	USD	92
2022-01-01 to 2022-09-30	-2,008,173	USD	273

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2023-09-30	54,318	USD
At 2022-12-31	100,014	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	354,862	USD	92
2023-01-01 to 2023-09-30	1,169,502	USD	273
2022-07-01 to 2022-09-30	441,673	USD	92
2022-01-01 to 2022-09-30	1,443,204	USD	273

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2023-09-30	20,228,692	USD
At 2022-12-31	17,425,587	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2023-09-30	7,772,254	USD
At 2022-12-31	6,882,947	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	667,497	USD	92
2023-01-01 to 2023-09-30	2,280,713	USD	273
2022-07-01 to 2022-09-30	588,475	USD	92
2022-01-01 to 2022-09-30	2,008,173	USD	273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2023-09-30	294,764,614	shares
At 2022-12-31	274,124,622	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2023-09-30	0	USD
At 2022-12-31	2,317	USD
At 2022-09-30	7,502	USD
At 2021-12-31	27,767	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2023-09-30	75,247,742	USD
At 2022-12-31	74,523,642	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2023-09-30	104,658	USD
At 2022-12-31	240,426	USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	-531,236	USD	92
2023-01-01 to 2023-09-30	-3,992,293	USD	273
2022-07-01 to 2022-09-30	-784,308	USD	92
2022-01-01 to 2022-09-30	-4,213,365	USD	273

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	336,620	USD	92
2023-01-01 to 2023-09-30	857,573	USD	273
2022-07-01 to 2022-09-30	201,818	USD	92
2022-01-01 to 2022-09-30	511,067	USD	273

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	223,904	USD	273
2022-01-01 to 2022-09-30	221,589	USD	273

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2023-07-01 to 2023-09-30	103,129	USD	92
2023-01-01 to 2023-09-30	-1,575,812	USD	273
2022-07-01 to 2022-09-30	-724,773	USD	92
2022-01-01 to 2022-09-30	-2,883,386	USD	273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	0	USD	273
2022-01-01 to 2022-09-30	0	USD	273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	0	USD	273
2022-01-01 to 2022-09-30	290,012	USD	273

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2023-01-01 to 2023-09-30	31,067	USD	273
2022-01-01 to 2022-09-30	15,233	USD	273

Inspect the source

Entity: CANNAPHARMARX, INC. / CIK 0001081938
Captured: 2026-09-20T05:20:43.396Z
SEC response SHA-256: 5d42938250dbbcfa19092cae39e1ddd591085d080af4dafac930684703fc6a67

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001081938.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))